An observational study in Agitation,Psychomotor, sponsored by Nova Pneuma Inc.. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Nova Pneuma Inc. · Observational
Low commercial usage of ADASUVE resulting in low patient enrollment. NPI has placed this study on hold until market uptake increases and makes it feasible to develop an alternative study design as recommended by FDA.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies in Psychomotor Agitation with a site in United States — 8 open to participants now, 14 under way, 4 of them phase 3. Psychomotor Agitation · United States.
Among the 108 studies in Psychomotor Agitation with a site in United States, this one has the largest planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2014, is one of 15 observational ones, and was the 62nd registered.
231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.
Browse Psychomotor Agitation studies →8 of the 108 studies in Psychomotor Agitation with a site in United States are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Brazil and 23 more countries
Ages 55–90
Bristol-Myers Squibb · Sites in United States, Argentina, Chile and 11 more countries
Ages 55–90
Celgene · Sites in United States, Argentina, Australia and 1 more country
Ages 55–90
Bernard (Barry) Baumel · Sites in United States
Ages 55–90
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Psychomotor Agitation studies recruiting now, 8 (40%) set no upper age limit and 7 (35%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 27 · Phase 3 29 · Phase 4 16
First in 1995; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 138 across 31 observational studies indexed under Psychomotor Agitation.
Median enrollment 92 across the 90 interventional studies, 136 across the 14 observational. Of the 84 that completed or were terminated, 43 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 108 have an industry lead sponsor. The 10 most frequent:
Nova Pneuma Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Nova Pneuma Inc. has 1 study filed under Psychomotor Agitation — fewer than ten, so there is no comparison to draw.
6 of the studies in Psychomotor Agitation with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05397639Phase 3Suven Life Sciences LimitedMasupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type | 2026-12 |
| NCT05543681IGC Pharma, LLCClinical Trial on Agitation in Alzheimer's Dementia | 2026-11 |
| NCT04075435Mclean HospitalCannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia | 2026-12 |
| NCT06052254Teikoku Pharma USA, Inc.Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type | 2027-05 |
| NCT07920497Anmed HealthWeighted Blankets for Agitation in Adults in the Intensive Care Unit | 2027-08-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 108 studies in Psychomotor Agitation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This postmarketing observational study will evaluate the safety of ADASUVE® in treating patients with agitation associated with schizophrenia or bipolar I disorder.
This is a multicenter, prospective, observational study conducted to evaluate the safety of ADASUVE treatment when used in real-world clinical setting in patients with agitation associated with schizophrenia or bipolar I disorder.
The primary objective of the study is to assess the safety of ADASUVE treatment in real-world clinical settings.
The secondary objective of the study is to describe the characteristics of patients, including demographic and baseline characteristics, after administration of ADASUVE treatment in real-world clinical settings.
The study population will consist of a non-randomized cohort of approximately 10000 adult men and women who have agitation associated with schizophrenia or bipolar I disorder (naïve and non-naïve to ADASUVE treatment).
The study population will consist of a non-randomized cohort of approximately 10000 adult men and women who have agitation associated with schizophrenia or bipolar I disorder (naïve and non-naïve to ADASUVE treatment), as determined by the treating health care provider, and who meet the eligibility criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients may be included in the study if they meet all of the following criteria:
Exclusion Criteria:
There are no exclusion criteria for this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ADASUVE (loxapine) inhalation powder in a 10-milligram (mg) single-use oral inhaler. One dose in a 24-hour period.
Drug: Loxapine 10 MG
Also known as: ADASUVE (loxapine) inhalation powder, NDA 022549
Evaluating frequency and nature of adverse events, serious adverse events and respiratory adverse events of special interest (AESIs) after administration of ADASUVE treatment in real-world clinical settings
Safety will be assessed by evaluating adverse events, serious adverse events, and respiratory AESIs within the study follow-up period after administration of ADASUVE treatment in real-world clinical settings.
Time frame: 24 hours
Patient demographics
The secondary measure of this study is patient characteristics, including demographic characteristics, after administration of ADASUVE treatment in real-world clinical settings.
Time frame: 24 hours
Patient baseline characteristics - medical history
The secondary measure of this study is patient characteristics, including baseline characteristic of medical history, after administration of ADASUVE treatment in real-world clinical settings.
Time frame: 24 hours
Patient baseline characteristics - prior medications
The secondary measure of this study is patient characteristics, including baseline characteristic of prior medications, after administration of ADASUVE treatment in real-world clinical settings.
Time frame: 24 hours
Exploratory objective - patient treatment satisfaction
The exploratory objective of the study is to assess patient perception of effectiveness (ranging from extremely dissatisfied to extremely satisfied), convenience (ranging from extremely inconvenient to extremely convenient), and overall satisfaction (ranging from extremely dissatisfied to extremely satisfied) using a modified Treatment Satisfaction Questionnaire for Medication (TSQM) after administration of ADASUVE treatment in real-world clinical settings. The TSQM is a modified version of the original TSQM version 1.4, a widely used generic measure to assess treatment satisfaction with medication. Scores range from 0 to 100, with higher scores representing higher satisfaction.
Time frame: 24 hours
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2014 (actual). Primary completion is estimated for Feb 2028, 159 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Feb 2027 → Feb 2028 and completion Sep 2027 → Sep 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Low commercial usage of ADASUVE resulting in low patient enrollment. NPI has placed this study on hold until market uptake increases and makes it feasible to develop an alternative study design as recommended by FDA.
Low commercial usage of ADASUVE resulting in low patient enrollment. NPI has placed this study on hold until market uptake increases and makes it feasible to develop an alternative study design as recommended by FDA.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nova Pneuma Inc.